168 related articles for article (PubMed ID: 12408135)
1. Reputations at stake.
New Sci; 2002 Mar; 173(2334):16. PubMed ID: 12408135
[No Abstract] [Full Text] [Related]
2. Corporate science v the right to know: is the rise of the private sector bringing down a cloak of secrecy?
Concar D
New Sci; 2002 Mar; 173(2334):14-6. PubMed ID: 12408133
[No Abstract] [Full Text] [Related]
3. Spitzer sues drug giant for deceiving doctors.
Wadman M
Nature; 2004 Jun; 429(6992):589. PubMed ID: 15190317
[No Abstract] [Full Text] [Related]
4. Putting GlaxoSmithKline to the test over paroxetine.
Doshi P
BMJ; 2013 Nov; 347():f6754. PubMed ID: 24222673
[No Abstract] [Full Text] [Related]
5. Gagged and bound.
New Sci; 2002 Mar; 173(2334):15. PubMed ID: 12408134
[No Abstract] [Full Text] [Related]
6. Drug-company data vaults to be opened.
Cressey D
Nature; 2013 Mar; 495(7442):419-20. PubMed ID: 23538802
[No Abstract] [Full Text] [Related]
7. Is GSK guilty of fraud?
Lancet
Lancet; 2004 Jun; 363(9425):1919. PubMed ID: 15194246
[No Abstract] [Full Text] [Related]
8. Court filing makes public my previously suppressed analysis of Paxil's effects.
Breggin PR
Ethical Hum Psychol Psychiatry; 2006; 8(1):77-84. PubMed ID: 16862720
[No Abstract] [Full Text] [Related]
9. Public access versus proprietary rights in genomic information: what is the proper role of intellectual property rights?
Mueller JM
J Health Care Law Policy; 2003; 6(2):222-40. PubMed ID: 15017961
[No Abstract] [Full Text] [Related]
10. Compounding risks to patients: selective disclosure is not an option.
McGoey L
Am J Bioeth; 2009 Aug; 9(8):35-6. PubMed ID: 19998156
[No Abstract] [Full Text] [Related]
11. Predictable materiality: a need for common criteria governing the disclosure of clinical trial results by publicly-traded pharmaceutical companies.
Cohen K; Cormier JW; Davar MV
J Contemp Health Law Policy; 2013; 29(2):201-32. PubMed ID: 23837261
[No Abstract] [Full Text] [Related]
12. British rethinking test rules after drug trial nearly kills 6.
Rosenthal E
N Y Times Web; 2006 Apr; ():A1, A6. PubMed ID: 16642579
[No Abstract] [Full Text] [Related]
13. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
Surprenant JA
Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
[TBL] [Abstract][Full Text] [Related]
14. Glaxo agrees to post results of drug trials on web site.
Harris G
N Y Times Web; 2004 Aug; ():C4. PubMed ID: 15540364
[No Abstract] [Full Text] [Related]
15. College was right not to disclose deliberations about chronic fatigue treatment trial, tribunal rules.
Dyer C
BMJ; 2013 Aug; 347():f5355. PubMed ID: 23996378
[No Abstract] [Full Text] [Related]
16. [Beyond "data sharing"].
Lamarca R; Herrera D
Med Clin (Barc); 2015 Jun; 144(12):548-9. PubMed ID: 25843632
[No Abstract] [Full Text] [Related]
17. British MRC reprimanded over clinical test record.
Dickson D
Nat Med; 1998 Jul; 4(7):752. PubMed ID: 9662351
[No Abstract] [Full Text] [Related]
18. Medicine. Moving toward transparency of clinical trials.
Zarin DA; Tse T
Science; 2008 Mar; 319(5868):1340-2. PubMed ID: 18323436
[No Abstract] [Full Text] [Related]
19. Drugmakers prefer silence on test data; firms violate US law by not registering trials.
Vedantam S
Washington Post; 2004 Jul; ():A1, A4. PubMed ID: 15290815
[No Abstract] [Full Text] [Related]
20. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
